Major Medical Breakthrough
India has developed its first indigenous superantibiotic, named Naphthromycin.
It is effective against bacteria resistant to older antibiotics.
Especially beneficial for diabetes and cancer patients suffering from infections during treatment.
Developed over 14 years of research.
👨⚕️ Why It’s Needed
Diabetic and cancer patients often suffer from breathing issues or infections.
Traditional antibiotics like azithromycin often fail due to resistance.
Naphthromycin offers relief by treating drug-resistant respiratory infections, especially pneumonia.
💊 How Powerful Is It?
Targets Streptococcus bacteria, responsible for 33% of pneumonia cases.
Claimed to be 10 times more potent than azithromycin.
Cures severe pneumonia in just 3 days.
Shown to be effective in trials across India, the US, and Europe.
A 97% success rate was reported in patients.
🏥 Who Developed It?
Created by Wockhardt Limited, Mumbai, with support from:
Department of Biotechnology (DBT)
BIRAC (Biotechnology industry Research Assistance Council)
Developed under a public-private partnership.
Brand name: Miknaf
Expected market launch: End of 2025
It will be affordable and included in the Ayushman Bharat scheme.
⚠️ Tackling Antibiotic Resistance
Antimicrobial resistance (AMR) causes approximately. 600,000 deaths annually in India.
Pneumonia causes nearly 2 million global deaths.
Naphthromycin fights multi-drug-resistant bacteria, a critical health threat.
🧬 Progress in Gene Therapy
India’s first indigenous gene therapy trial for hemophilia succeeded.
Conducted at Christian Medical College, Vellore, with DBT support.
60–70% of patients improved, with no bleeding episodes.
Results published in the New england Journal of Medicine.
Disclaimer:
The information contained in this article is for general informational purposes only. While we strive to ensure accuracy, we make no warranties or representations of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the content. Any reliance you place on the information is strictly at your own risk. The views, opinions, or claims expressed in this article are those of the author and do not necessarily reflect the official policy or position of any organization mentioned. We disclaim any liability for any loss or damage arising directly or indirectly from the use of this article.
click and follow Indiaherald WhatsApp channel